Boehringer's leukemia candidate wins breakthrough status from FDA

09/19/2013 | Healio · PharmaTimes (U.K.)

Boehringer Ingelheim's pololike kinase inhibitor volasertib won breakthrough-therapy designation from the FDA as a potential treatment for acute myeloid leukemia. The approval was based on data from a midstage trial that showed volasertib, in combination with low-dose cytarabine, improved overall and event-free survival compared with cytarabine alone.

View Full Article in:

Healio · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL